IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v35y2017i11d10.1007_s40273-017-0538-9.html
   My bibliography  Save this article

The Indonesian EQ-5D-5L Value Set

Author

Listed:
  • Fredrick Dermawan Purba

    (Erasmus MC University Medical Center
    Padjadjaran University)

  • Joke A. M. Hunfeld

    (Erasmus MC University Medical Center)

  • Aulia Iskandarsyah

    (Padjadjaran University)

  • Titi Sahidah Fitriana

    (YARSI University)

  • Sawitri Supardi Sadarjoen

    (Padjadjaran University)

  • Juan Manuel Ramos-Goñi

    (EuroQol Research Foundation)

  • Jan Passchier

    (VU University)

  • Jan J. V. Busschbach

    (Erasmus MC University Medical Center)

Abstract

Background The EQ-5D is one of the most used generic health-related quality-of-life (HRQOL) instruments worldwide. To make the EQ-5D suitable for use in economic evaluations, a societal-based value set is needed. Indonesia does not have such a value set. Objective The aim of this study was to derive an EQ-5D-5L value set from the Indonesian general population. Methods A representative sample aged 17 years and over was recruited from the Indonesian general population. A multi-stage stratified quota method with respect to residence, gender, age, level of education, religion and ethnicity was utilized. Two elicitation techniques, the composite time trade-off (C-TTO) and discrete choice experiments (DCE) were applied. Interviews were undertaken by trained interviewers using computer-assisted face-to-face interviews with the EuroQol Valuation Technology (EQ-VT) platform. To estimate the value set, a hybrid regression model combining C-TTO and DCE data was used. Results A total of 1054 respondents who completed the interview formed the sample for the analysis. Their characteristics were similar to those of the Indonesian population. Most self-reported health problems were observed in the pain/discomfort dimension (39.66%) and least in the self-care dimension (1.89%). In the value set, the maximum value was 1.000 for full health (health state ‘11111’) followed by the health state ‘11112’ with value 0.921. The minimum value was −0.865 for the worst state (‘55555’). Preference values were most affected by mobility and least by pain/discomfort. Conclusions We now have a representative EQ-5D-5L value set for Indonesia. We expect our results will promote and facilitate health economic evaluations and HRQOL research in Indonesia.

Suggested Citation

  • Fredrick Dermawan Purba & Joke A. M. Hunfeld & Aulia Iskandarsyah & Titi Sahidah Fitriana & Sawitri Supardi Sadarjoen & Juan Manuel Ramos-Goñi & Jan Passchier & Jan J. V. Busschbach, 2017. "The Indonesian EQ-5D-5L Value Set," PharmacoEconomics, Springer, vol. 35(11), pages 1153-1165, November.
    • Handle: RePEc:spr:pharme:v:35:y:2017:i:11:d:10.1007_s40273-017-0538-9
    DOI: 10.1007/s40273-017-0538-9
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-017-0538-9
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-017-0538-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Drummond, Michael F. & Sculpher, Mark J. & Claxton, Karl & Stoddart, Greg L. & Torrance, George W., 2015. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 4, number 9780199665884.
    2. Arthur E. Attema & Matthijs M. Versteegh & Mark Oppe & Werner B. F. Brouwer & Elly A. Stolk, 2013. "Lead Time Tto: Leading To Better Health State Valuations?," Health Economics, John Wiley & Sons, Ltd., vol. 22(4), pages 376-392, April.
    3. Mark Oppe & Kim Rand-Hendriksen & Koonal Shah & Juan M. Ramos‐Goñi & Nan Luo, 2016. "EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes," PharmacoEconomics, Springer, vol. 34(10), pages 993-1004, October.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Hari Setyowibowo & Fredrick Dermawan Purba & Joke A M Hunfeld & Aulia Iskandarsyah & Sawitri S Sadarjoen & Jan Passchier & Marit Sijbrandij, 2018. "Quality of life and health status of Indonesian women with breast cancer symptoms before the definitive diagnosis: A comparison with Indonesian women in general," PLOS ONE, Public Library of Science, vol. 13(7), pages 1-11, July.
    2. Eliza L. Y. Wong & Juan Manuel Ramos-Goñi & Annie W. L. Cheung & Amy Y. K. Wong & Oliver Rivero-Arias, 2018. "Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(2), pages 235-247, April.
    3. Fredrick Dermawan Purba & Joke A M Hunfeld & Aulia Iskandarsyah & Titi Sahidah Fitriana & Sawitri S Sadarjoen & Jan Passchier & Jan J V Busschbach, 2018. "Quality of life of the Indonesian general population: Test-retest reliability and population norms of the EQ-5D-5L and WHOQOL-BREF," PLOS ONE, Public Library of Science, vol. 13(5), pages 1-20, May.
    4. Touré, Moustapha & Poder, Thomas G., 2024. "Differences in health utilities between cancer patients and the general population: The case of Quebec using the SF-6Dv2," Social Science & Medicine, Elsevier, vol. 351(C).
    5. Kelleher, Dan & Barry, Luke & Hobbins, Anna & O'Neill, Stephen & Doherty, Edel & O'Neill, Ciaran, 2020. "Examining the transnational health preferences of a group of Eastern European migrants relative to a European host population using the EQ-5D-5L," Social Science & Medicine, Elsevier, vol. 246(C).
    6. Hobbins, Anna P. & Barry, Luke & Kelleher, Dan & Shah, Koonal & Devlin, Nancy & Ramos Goni, Juan Manuel & O’Neill, Ciaran, 2020. "Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland," Health Policy, Elsevier, vol. 124(6), pages 639-646.
    7. Hsiang-Wen Lin & Chia-Ing Li & Fang- Ju Lin & Jen-Yu Chang & Churn-Shiouh Gau & Nan Luo & A Simon Pickard & Juan M Ramos Goñi & Chao-Hsiun Tang & Chien-Ning Hsu, 2018. "Valuation of the EQ-5D-5L in Taiwan," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-16, December.
    8. Finch, Aureliano Paolo & Meregaglia, Michela & Ciani, Oriana & Roudijk, Bram & Jommi, Claudio, 2022. "An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration," Social Science & Medicine, Elsevier, vol. 292(C).
    9. Mina Bahrampour & Joshua Byrnes & Richard Norman & Paul A. Scuffham & Martin Downes, 2020. "Discrete choice experiments to generate utility values for multi-attribute utility instruments: a systematic review of methods," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 983-992, September.
    10. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020. "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, vol. 246(C).

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jen-Yu Amy Chang & Chien-Ning Hsu & Juan Manuel Ramos-Goñi & Nan Luo & Hsiang-Wen Lin & Fang-Ju Lin, 2024. "Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(6), pages 1041-1055, August.
    2. Andrew Lloyd & Kim Rand & Cleo Pike & Crispin Ellis, 2024. "Preference-based utility weights for the Individualized Neuromuscular Quality of Life Questionnaire (INQoL), with a focus on non-dystrophic myotonia (NDM)," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(8), pages 1461-1469, November.
    3. Stefan A. Lipman & Arthur E. Attema & Matthijs M. Versteegh, 2022. "Correcting for discounting and loss aversion in composite time trade‐off," Health Economics, John Wiley & Sons, Ltd., vol. 31(8), pages 1633-1648, August.
    4. Patricia Cubi-Molla & Koonal Shah & Kristina Burström, 2018. "Experience-Based Values: A Framework for Classifying Different Types of Experience in Health Valuation Research," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(3), pages 253-270, June.
    5. Spencer, Anne & Rivero-Arias, Oliver & Wong, Ruth & Tsuchiya, Aki & Bleichrodt, Han & Edwards, Rhiannon Tudor & Norman, Richard & Lloyd, Andrew & Clarke, Philip, 2022. "The QALY at 50: One story many voices," Social Science & Medicine, Elsevier, vol. 296(C).
    6. Chiranjeev Sanyal & Don Husereau, 2020. "Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 375-392, June.
    7. Andrew J. Mirelman & Miqdad Asaria & Bryony Dawkins & Susan Griffin & Richard Cookson & Peter Berman, 2020. "Fairer Decisions, Better Health for All: Health Equity and Cost-Effectiveness Analysis," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 4, pages 99-132, World Scientific Publishing Co. Pte. Ltd..
    8. Christopher M Doran & Irina Kinchin, 2020. "Economic and epidemiological impact of youth suicide in countries with the highest human development index," PLOS ONE, Public Library of Science, vol. 15(5), pages 1-11, May.
    9. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    10. Dongzhe Hong & Lei Si & Minghuan Jiang & Hui Shao & Wai-kit Ming & Yingnan Zhao & Yan Li & Lizheng Shi, 2019. "Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review," PharmacoEconomics, Springer, vol. 37(6), pages 777-818, June.
    11. Simon Pol & Paula Rojas Garcia & Fernando Antoñanzas Villar & Maarten J. Postma & Antoinette D. I. Asselt, 2021. "Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting," PharmacoEconomics, Springer, vol. 39(12), pages 1355-1363, December.
    12. Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
    13. Omar B. Da'ar & Abdi A. Gele, 2023. "Tuberculosis in a weak health system, conflict and fragile zone: The monetary value of human lives lost associated with deaths of persons older than 14 years in Somalia," International Journal of Health Planning and Management, Wiley Blackwell, vol. 38(1), pages 53-68, January.
    14. Anna Nicolet & Antoinette D I van Asselt & Karin M Vermeulen & Paul F M Krabbe, 2020. "Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-18, July.
    15. McNamara, Simon & Tsuchiya, Aki & Holmes, John, 2021. "Does the UK-public's aversion to inequalities in health differ by group-labelling and health-gain type? A choice-experiment," Social Science & Medicine, Elsevier, vol. 269(C).
    16. Nikolai Mühlberger & Gaby Sroczynski & Artemisa Gogollari & Beate Jahn & Nora Pashayan & Ewout Steyerberg & Martin Widschwendter & Uwe Siebert, 2021. "Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(8), pages 1311-1344, November.
    17. Zachary Tirrell & Alicia Norman & Martin Hoyle & Sean Lybrand & Bonny Parkinson, 2024. "Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee," PharmacoEconomics, Springer, vol. 42(11), pages 1287-1300, November.
    18. Yasuhiro Hagiwara & Takeru Shiroiwa, 2022. "Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches," Medical Decision Making, , vol. 42(5), pages 672-683, July.
    19. Cameron Morgan & Cam Donaldson & Emily Lancsar & Stavros Petrou & Lazaros Andronis, 2024. "Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study," PharmacoEconomics, Springer, vol. 42(11), pages 1267-1277, November.
    20. Dina Jankovic & Pedro Saramago Goncalves & Lina Gega & David Marshall & Kath Wright & Meena Hafidh & Rachel Churchill & Laura Bojke, 2022. "Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis," PharmacoEconomics - Open, Springer, vol. 6(3), pages 377-388, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:35:y:2017:i:11:d:10.1007_s40273-017-0538-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.